Reuters logo
BRIEF-Ose Immunotherapeutics reports H1 operating loss of 7.3 million euros
September 7, 2017 / 4:45 PM / 19 days ago

BRIEF-Ose Immunotherapeutics reports H1 operating loss of 7.3 million euros

Sept 7 (Reuters) - OSE IMMUNOTHERAPEUTICS SA:

* ‍AVAILABLE CASH AS OF JUNE 30, 2017 OF EUR 20.5 MILLION​

* ‍IN H1 EUR 2.8 MILLION TURNOVER (DUE TO SPREAD OF EUR 10.25 MILLION OF REVENUE FROM LICENSE OPTION ON OSE-127 SIGNED WITH SERVIER)​

* ‍FR104 (CD28-ANTAGONIST): PHASE 2 CLINICAL INITIATION EXPECTED IN 2018 IN RHEUMATOID ARTHRITIS BY LICENSEE JANSSEN BIOTECH​

* ‍OSE-172 (SIRPΑ-ANTAGONIST, MYELOID CHECKPOINT INHIBITOR): INITIATION OF PHASE 1/2 CLINICAL TRIAL EXPECTED IN 2018 IN IMMUNO-ONCOLOGY​

* ‍OSE-127 (IL-7R ANTAGONIST): INITIATION OF PHASE 1 CLINICAL TRIAL EXPECTED IN 2018 IN AUTOIMMUNE DISEASES​

* ‍WE EXPECT TO ENTER CLINIC IN 2018 WITH OSE-172 AND OSE-127​

* H1 OPERATING RESULT LOSS EUR 7.3‍​ MILLION VERSUS PROFIT EUR 22.3 MILLION YEAR AGO

* H1 NET RESULT LOSS EUR 6.3‍​ MILLION VERSUS PROFIT EUR 24.5 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below